Effective immediately, CADTH has revised the category 1 requirements of for new combination products (funded components) and new combination products designated by CADTH to undergo a tailored CDR review.

Key revisions include additional space for capturing the results of key clinical studies and publicly available listing status for the individual components of the combination.

For more details, go to: http://www.cadth.ca/en/products/cdr/cdr-update/cdr-update-110?utm_source=CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=1a008b0317-E_Alert_CDR_Update+109&utm_medium=email&utm_term=0_4df26bdb5b-1a008b0317-197490029